Market Overview

Teva-Lonza JV Says Evaluating Biosimilars Opportunities

Share:

The Teva-Lonza Joint Venture issued the following statement today:

The potential to develop, manufacture and market affordable, efficacious and safe biosimilars remains an area of significant opportunity for both Teva and Lonza.

The Teva Lonza partnership continues to explore this opportunity. Both as partners and individual companies, Teva and Lonza are focused on finding the best routes to realizing the benefits that safe biosimilars of certain biologic pharmaceuticals will bring to the healthcare community.

There is significant regulatory uncertainty in the biosimilars arena at present. Therefore, both companies are taking a measured approach, choosing to fully evaluate the prevailing regulatory and commercial circumstances before agreeing on further long-term investment decisions that both partners are comfortable with.

Posted-In: News

 

Related Articles (TEVA)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Glitter Is Wearing Off

Sarepta Says Eteplirsen Shows Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study